Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is
characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas). Within the
LAM patient population is a subset of patients who develop chylous effusions and
lymphangioleiomyomas. Treatment of many of these symptoms has been ineffective. Previous
studies with somatostatin and octreotide in other clinical settings have shown reduction in
chylous effusions. This study assesses the effectiveness of octreotide in symptomatic
patients with LAM, lymphangioleiomyomas and/or chylous effusions/ascites, peripheral
lymphedema and chyluria.